Anticoagulant antithrombotic dual inhibitors comprising a biotin label
The present invention relates compounds of the formula: oligosaccharide-spacer-(GpIIb/IIIa antagonist), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is a bond or an essentially pharmacologically inactive linking residue; the GpIIb/IIIa antagonist is a residue mimicking the RGD and/or K(QA)GD fragment of fibrinogen, comprising a carboxylate moiety and a basic moiety located within the residue at a distance of 10-20 Å from each other; or a pharmaceutically acceptable salt thereof or a prodrug or a solvate thereof; wherein the compound of formula I further comprises at least one covalent bond with a biotin label or an analogue thereof. The compounds of the invention have antithrombotic activity and can be used in treating or preventing thrombotic diseases. The antithrombotic activity of the compound of this invention can be neutralized in case of emergency upon administration of avidin, streptavidin and analogues thereof having high biotin affinity.
1. An antithrombotic compound of the formula I
oligosaccharide-spacer-GpIIb/IIIa antagonist (I),
wherein the oligosaccharide is a negatively charged pentasaccharide residue of Formula B
wherein R1 is OCH 3 or OSO 3 − , the charge being compensated by positively charged counterions;
the spacer is an essentially pharmacologically inactive linking residue;
the GpIIb/IIIa antagonist is a residue derived from tirofiban (MK 383);
or a pharmaceutically acceptable salt thereof;
wherein the spacer of the compound of formula I comprises a covalent bond with a biotin label.
2. The compound of any one of claim 1 , wherein the spacer of the compound of formula I comprises one covalent bond with a biotin analogue of the formula —(CH 2 ) 4 —X-BT, wherein X═NH, N(1-4C)alkyl, NH—CH(CH 2 OH)—CH 2 —C(O)—NH, NH—CH(CH 3 )—CH 2 —C(O)—NH, NH—CH(COOH)—CH 2 —C(O)—NH or NH—CH(CH 2 COOH)—CH 2 —C(O)—NH, and wherein BT is the label
3. The compound of claim 2 , being
4. The compound of claim 3 , being in the form of its sodium salt.
5. The compound of claim 4 , being
6. A pharmaceutical composition comprising the compound of any one of claim 1 and claims 2 - 5 and pharmaceutically suitable auxiliaries.
7. A method for treating thrombosis in a patient, the method comprising administering to the patient an effective amount of the compound according to claim 1 .